Status:
COMPLETED
ATHN 11: Liver Transplantation Outcomes Study
Lead Sponsor:
American Thrombosis and Hemostasis Network
Collaborating Sponsors:
BioMarin Pharmaceutical
Conditions:
Hemophilia A and B
Liver Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed as a multi-center, observational cohort study of participants with hemophilia A and B who have and have not undergone liver transplantation. Participants will be asked to comple...
Detailed Description
At a time when gene therapy is becoming a reality for individuals with hemophilia A and B, little is known about long-term cures. Yet, there are few data to provide real life testing of the impact of ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Participants who meet the following inclusion criteria are eligible for enrollment into the study:
- Congenital hemophilia A or B of any severity, who have and have not undergone a liver transplant;
- Age \> 18; and
- Sex assigned at birth was male
- Exclusion Criteria
- Participants who fall into any of the following exclusion criteria at the time of screening are not eligible for enrollment into the study:
- 1\. Age \<18.
Exclusion
Key Trial Info
Start Date :
June 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04055051
Start Date
June 18 2020
End Date
December 1 2022
Last Update
May 10 2023
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Orthopaedic Institute for Children Hemophilia Program
Los Angeles, California, United States, 90007
2
University of California, San Francisco
San Francisco, California, United States, 94117
3
Bleeding and Clotting Disorders Institute
Peoria, Illinois, United States, 61614
4
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana, United States, 46260